Boothbay Fund Management’s aTyr Pharma ATYR Stock Holding History

Boothbay Fund Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,568	Closed	-$44K	–	1827
2025 Q1	$44K	Hold	14,568	–	–	﹤0.01%	1289
2024 Q4	$52.7K	Buy	+14,568	New	+$44.1K	﹤0.01%	1350
2023 Q4	–	Sell	-36,000	Closed	-$56.9K	–	2060
2023 Q3	$56.9K	Hold	36,000	–	–	﹤0.01%	1621
2023 Q2	$77.8K	Sell	36,000 -44,000	-55%	-$96K	﹤0.01%	1640
2023 Q1	$168K	Buy	+80,000	New	+$175K	﹤0.01%	1794
2021 Q4	–	Sell	-56,329	Closed	-$511K	–	2286
2021 Q3	$511K	Buy	56,329 +23,899	+74%	+$143K	0.01%	1072
2021 Q2	$158K	Hold	32,430	–	–	0.01%	1597
2021 Q1	$144K	Sell	32,430 -9,250	-22%	-$43.5K	0.01%	1432
2020 Q4	$162K	Buy	+41,680	New	+$152K	0.01%	1127
2019 Q2	–	Sell	-6,748	Closed	-$52K	–	920
2019 Q1	$52K	Hold	6,748	–	–	0.01%	700
2018 Q4	$47K	Hold	6,748	–	–	0.01%	591
2018 Q3	$77K	Sell	6,748 -737	-10%	-$8.06K	0.01%	734
2018 Q2	$95K	Buy	+7,485	New	+$177K	0.01%	687

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's ATYR Position: Q2 2025 in Review

Boothbay Fund Management sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 14,568 shares — an estimated $44K sold.

Boothbay Fund Management first reported a position in ATYR in Q2 2018 and held it in 13 quarters. The position peaked at $511K in Q3 2021. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

Boothbay Fund Management reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
Boothbay Fund Management sold 14,568 aTyr Pharma shares in Q2 2025, an estimated $44K.
Boothbay Fund Management first reported a position in aTyr Pharma in Q2 2018 and held it in 13 quarters.
Boothbay Fund Management's aTyr Pharma position peaked at $511K in Q3 2021.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.